1. ALLA AKTIER
  2. NYHETER
  3. MEDIVIR

Medivir

Nyheter Medivir Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Medivir to present at the Redeye Technology & Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today announces that the company will participate at the Redeye Technology & Life Science Day, tomorrow, December 3, 2024.

CEO Jens Lindberg will participate in an In Focus interview at 10.40 CET, led by Redeye analyst Richard Ramanius. The interview will focus on the recently presented data at the ESMO conference and how they strengthen the ambition to make fostrox + Lenvima® the first, approved treatment option in second-line HCC.
 
 
The presentation is live broadcasted and can be followed at the event page;
https://www.redeye.se/events/1038747/redeye-technology-life-science-day
The presentation will be available on Medivir’s website after the meeting.

For additional information, please contact;
Magnus Christensen, CFO, Medivir AB
Telephone: +46 8 5468 3100
E-mail: magnus.christensen@medivir.com

About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com.

Attachments
Press Release (PDF)

Datum 2024-12-02, kl 10:00
Källa MFN
Bifogade filer
Press Release (PDF)